Tumor-agnostic data supporting approval demonstrated an overall response rate (ORR) of 44% across multiple tumor types FDA simultaneously grants traditional approval in adults with locally advanced or ...
Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions. The Food and Drug Administration (FDA) granted an accelerated approval to ...
A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation. Background: RET gene alterations (mutations and fusions) leading to constitutive ...
“Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired resistance to lorlatinib after 6 months on ...
An expert discusses the recent approval for Retevmo for RET-positive pediatric thyroid cancer and ongoing research for this patient population. The recent Food and Drug Administration (FDA) approval ...
CHENGDU, China, Sept. 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged ...
The National Institute for Health and Care Excellence (NICE) has issued final guidance approving selpercatinib (Retsevmo, Eli Lilly) for treating advanced thyroid cancer with RET alterations both in ...
Erratum: Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study Erratum: Prognostic Value of Neurotrophic ...
We have previously highlighted Loxo Oncology (Nasdaq: LOXO) in this space regarding its partnership with Illumina on next generation cancer diagnostics. One of the collaborative efforts involves a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback